The growing popularity and rising demand for peptide-based drugs, specifically the GLP-1 peptide drugs, have garnered the attention of stakeholders to further invest in research and developments of peptides.

Peptides represent one of the fastest growing segments of the pharmaceutical industry. This can be attributed to the rapidly growing pipeline of peptide-based therapeutics, driven by the need for effective and personalized pharmacological interventions.

The global peptide synthesis market size is estimated to grow from USD 2.8 billion in 2024 to USD 5.1 billion by 2035, representing a CAGR of 5.5% during the forecast period 2024-2035.

There has been a significant rise in the partnership activity in the peptide synthesis industry; majority of the collaborations were inked specifically for peptide API manufacturing. It is worth noting that over the past few years, an inconsistent trend in partnership activity in this domain has been observed. However, a significant increase has been witnessed in 2023 (till October), wherein 11 agreements were signed in peptide synthesis domain. Notable examples of recent agreements include (in reverse chronological order) those signed between PolyPeptide and Peptide Sciences Laboratory of the University of KwaZulu-Natal (UKZN) (October 2023), AmbioPharm and CombiGene (September 2023) and Otsuka Chemical and Yokogawa Electric (March 2023). Manufacturing agreements emerged as the most popular type of partnership model adopted by companies in this domain; 15 such agreements have been signed during the given time period. This is followed by acquisitions (6), service alliances (4) and technology integration / utilization agreements (4).

To keep pace with the growing demand for peptides, companies have made significant investments to expand their facilities and capacities. In order to keep up with the growing business requirements, service providers are heavily investing in either expanding their existing facilities / capacities or constructing / acquiring new facilities in other geographies. More than 75% of the expansion initiatives undertaken in this domain were reported in 2023. This can be attributed to the rising demand for peptide-based drugs and preferred choice of outsourcing. It is important to note that majority of the expansion occurred at facilities based in North America; of these, 67% are instances of new facility establishment and capacity expansions.

The domain has witnessed a gradual increase in clinical research activity over the given time period. It is worth highlighting that the number of clinical trials for peptide therapeutics witnessed a notable increase from 2021 (96) to 2022 (163). This can be attributed to the incessant efforts of several industry / non-industry players that are actively evaluating peptide therapeutics for the treatment of a myriad of disease indications. Furthermore, majority of the centers in all the regions are focused on evaluating peptide therapeutics for metabolic disorders, followed by oncological and kidney disorders. Further, it is worth highlighting that presently, the maximum number of clinical trials related to the treatment of cardiovascular disorders are conducted in North America.

Research Methodology

Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Peptide Synthesis Market.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs. 

To get sample report visit@

https://www.rootsanalysis.com/reports/peptide-therapeutics-manufacturing/request-sample.html